Publications (85) SARA LÓPEZ TARRUELLA COBO publications

filter_list

2025

  1. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer

    npj Breast Cancer, Vol. 11, Núm. 1

  2. Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies

    Oncologist, Vol. 30, Núm. 4

  3. TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

    Annals of Oncology, Vol. 36, Núm. 2, pp. 158-171

2024

  1. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study

    Breast Cancer Research and Treatment, Vol. 203, Núm. 1, pp. 163-172

  2. Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain

    PharmacoEconomics - Open, Vol. 8, Núm. 6, pp. 887-896

  3. Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort

    Breast Cancer Research and Treatment, Vol. 206, Núm. 3, pp. 551-559

  4. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

    Breast Cancer Research and Treatment, Vol. 206, Núm. 2, pp. 317-328

  5. Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2160-2169

2023

  1. Assessment of a Genomic Assay in Patients with ERBB2 -Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy with or Without Pertuzumab

    JAMA Oncology, Vol. 9, Núm. 6, pp. 841-846

  2. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

    Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795

  3. Impact of the COVID-19 Lockdown on Physical Activity Levels and Health Parameters in Young Adults with Cancer

    Current Oncology, Vol. 30, Núm. 6, pp. 5395-5408

  4. Laser transfer for circulating tumor cell isolation in liquid biopsy

    International Journal of Bioprinting, Vol. 9, Núm. 4, pp. 1-14

  5. Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry

    Breast Cancer Research and Treatment, Vol. 201, Núm. 2, pp. 151-159

2022

  1. A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

    Journal of Visualized Experiments, Vol. 2022, Núm. 187

  2. A prospective observational study for a Federated Artificial Intelligence solution for moniToring mental Health status after cancer treatment (FAITH): study protocol

    BMC Psychiatry, Vol. 22, Núm. 1

  3. HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping

    Cancers, Vol. 14, Núm. 3

  4. How we treat HR-positive, HER2-negative early breast cancer

    Future oncology (London, England), Vol. 18, Núm. 8, pp. 1003-1022

  5. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

    The Lancet. Oncology, Vol. 23, Núm. 1, pp. 149-160

  6. The importance of physical exercise in cardiovascular fitness in breast cancer survivors. A cross-sectional study: women in Motion 2.0

    Supportive Care in Cancer, Vol. 30, Núm. 8, pp. 6745-6754

2021

  1. Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts

    Scientific Reports, Vol. 11, Núm. 1